Feature

Spectral combining diagnostics with targeted therapy in novel approach to septic shock

Spectral Medical (TSX: EDT) is seeking to improve outcomes for millions of patients with life-threatening endotoxic septic shock (ESS), by combining its targeted diagnostic, Endotoxin Activity Assay (EAA), with its...

November 12, 2024

Feature

Conavi’s recent RTO fuels trajectory of world’s first and only hybrid intravascular imaging system combining co-registered IVUS + OCT

Conavi Medical (TSXV:CNVI) is leveraging its recent reverse merger (RTO) with Titan Medical to accelerate the wide-spread adoption of its breakthrough imaging platform, the next-generation Novasight Hybrid System...

November 5, 2024

Feature

Creyon Bio reimagining drug development with engineered on-demand oligonucleotide therapies

Closely-held Creyon Bio is developing a faster, more cost-effective path to new medicines for rare and common diseases through the AI-enabled engineering of oligonucleotide-based therapies (OBMs) that deliver safe...

October 15, 2024

Feature

OSE Immunotherapeutics breaking through the therapeutic ceiling with first-in-class immunotherapies

OSE Immunotherapeutics (ISIN:FR0012127173; Mnemo:OSE) is developing and partnering therapies to control the immune system for immuno-oncology (IO) and immuno-inflammation with first-in-class immunotherapies from target...

October 1, 2024

NEWS

Perimeter’s B-Series OCT with ImgAssist AI demonstrates super-superiority compared to standard-of-care in breast cancer surgery pivotal clinical trial

Just a few of the companies we’ve highlighted along the way

Giving healthcare companies and their stories the exposure they deserve.

Spectral combining diagnostics with targeted therapy in novel approach to septic shock

Conavi’s recent RTO fuels trajectory of world’s first and only hybrid intravascular imaging system combining co-registered IVUS + OCT

Creyon Bio reimagining drug development with engineered on-demand oligonucleotide therapies

OSE Immunotherapeutics breaking through the therapeutic ceiling with first-in-class immunotherapies

NEWS

Perimeter’s B-Series OCT with ImgAssist AI demonstrates super-superiority compared to standard-of-care in breast cancer surgery pivotal clinical trial

MOBILion launches proteomics advisory board

Neurizon reports positive results from preclinical study of NUZ-001 in ALS

Adverum announces positive 52-week LUNA results and four-year OPTIC data

Therma Bright to spin off consumer product portfolio creating new company

MindMed names Gregg Pratt as chief regulatory and quality assurance officer

AC Immune announces positive interim results from study of ACI-7104.056 in Parkinson’s

Opthea names Kathy Connell to BOD

Moleculin amends protocol for Phase 3 trial of Annamycin for AML

Just a few of the companies we’ve highlighted along the way

General

More